A PYMNTS Company

US: Baltimore files antitrust suit over cost of cancer drug

By  |  May 21, 2019

Maryland’s biggest city has filed an antitrust lawsuit against a biotechnology company it accuses of inflating costs for its prostate cancer drug, reported the Washington Post.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Baltimore announced Monday, May 20, that it has filed suit to recover damages from Janssen Biotech, Inc, part of Johnson & Johnson. Among other things, Baltimore alleges that Janssen pursued “sham litigation” and tried inflating costs for Zytiga, a prostate cancer drug that’s earned billions of dollars.

    Baltimore claims its prescription drug plans were unjustly forced into paying “inflated” prices since 2016 when the company’s original patent expired.

    Michelle Larkin is a Janssen spokeswoman. She said in a Monday email that the biotech company “stands by its decision to defend the validity and infringement of the relevant patent.”

    Full Content: Washington Post

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.